BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-120@catalystbrief.girapphe.com
DTSTAMP:20261117T181555Z
LAST-MODIFIED:20261117T181555Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Serum Institute of India Pvt. Ltd. — Cervavac as three d
 ose regimen [Dec 2026]
DESCRIPTION:Phase 3 primary completion: Clinical Study to Evaluate SIIPL qH
 PV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years.\nSource
 : https://clinicaltrials.gov/study/NCT06281119\nhttps://catalystbrief.gira
 pphe.com/e/120?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/120?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
